Background <p>Immunotherapy resistance in microsatellite-stable colorectal cancer (CRC) remains a major therapeutic challenge. Recent strategies to overcome the immunosuppressive tumor microenvironment have focused on reactivating innate immune pathways, particularly the cyclic GMP-AMP synthase-stimulator of interferon genes (cGAS-STING) axis, which links cytosolic DNA sensing to proinflammatory cytokine production and T cell activation. Although STING agonists show promise, their clinical application is…
Targeting VCP enhances colorectal cancer therapy through STING stabilization
Journal for ImmunoTherapy of Cancer | | Zhu, H., Ge, F., Dai, J., Yang, S., Yuan, T., Zheng, C., Dong, X., Hu, R., Zhou, T., He, Q., Yang, B., Zhu, H.
Topics: colorectal-cancer, blood-cancer, immunotherapy, new-technology, research
Read the full article at Journal for ImmunoTherapy of Cancer